

**THINK TANK ON
ADVANCING
GASTROESOPHAGEAL
CANCER RESEARCH**

NOVEMBER 17-18, 2022, BOSTON, MA

Meeting Program

PRESENTED BY

TargetCancer Foundation



TargetCancer
Foundation

Boston College Club
100 Federal Street, Boston, MA



DEAR COLLEAGUES,

Thank you for joining us today for the sixth TargetCancer Foundation Think Tank on Advancing Gastroesophageal Cancer Research. We are grateful for your insights and expertise, and hope that today's presentations and conversations will lead to new initiatives and powerful collaborations as we work towards the common goal of accelerating research and identifying effective treatments for patients with gastroesophageal cancers.

This meeting would not be possible without the guidance and leadership of our Steering Committee, and I am grateful to Drs. Julian Abrams, Adam Bass, James Goldenring, Sam Klempner, Monika Laszkowska, and Matt Stachler for all of their work in developing our agenda.

My sincere thanks as well to all of our speakers. Whether they traveled from across the country or from across town, they have taken time out of very busy schedules to be with us today, and I am grateful for their generosity in sharing their expertise with all of us.

Finally, thank you also to our sponsors for their dedicated support of this meeting, and for their focus on developing treatments for patients with gastroesophageal cancers.

Sincerely,

A handwritten signature in blue ink, appearing to read "Jim Palma".

Jim Palma
Executive Director
TargetCancer Foundation

2022 THINK TANK STEERING COMMITTEE

Julian Abrams, MD, MS, Columbia University Irving Medical Center
Adam Bass, MD, Novartis Institute for Biomedical Research
James Goldenring, MD, PhD, Vanderbilt University Medical Center
Sam Klempner, MD, Massachusetts General Hospital
Monika Laszkowska, MD, MS, Memorial Sloan Kettering Cancer Center
Matthew Stachler, MD, PhD, University of California, San Francisco

KEYNOTE SPEAKER



Dana Deighton is an accomplished professional with experience in corporate marketing, publishing, and partner/project management. After 20+ years at National Geographic, she spent three years at Inspire, a leading social network for health that connects patients and caregivers in a safe permission-based environment, and is now Associate Director of Outreach and Strategic Partnerships at Scripps Research working to drive enrollment for NIH's All of Us Research Program, a

historic effort to accelerate research and improve health by gathering data from one million or more people living in the United States. Also active in the cancer advocacy space, Dana mentors other patients and serves as an Executive Board Member of the Esophageal Cancer Action Network and as co-chair on the Patient and Family Advisory Council for the University of Maryland Greenebaum Comprehensive Cancer Center.

Dana lives in Alexandria, VA, with her husband and has a high school senior and two young adults.

AGENDA - DAY 1

THURSDAY, NOVEMBER 17

9:00 AM NETWORKING BREAKFAST & REGISTRATION

10:00 AM WELCOME and MEETING OVERVIEW

Adam Bass, MD, *Novartis Institute for Biomedical Research*

10:10 AM WELCOME and TCF-001 TRACK INTRODUCTION

Jim Palma, Executive Director, *TargetCancer Foundation*

10:25 AM PATIENT KEYNOTE

Dana Deighton

10:45 AM SESSION 1: CHROMOSOMAL INSTABILITY (CIN)

Lee Zou, PhD, *Massachusetts General Hospital*

David Gallo, PhD, *Repare Therapeutics*

Discussion moderated by Adam Bass, MD

12:15 PM NETWORKING LUNCH

1:15 PM SESSION 2: MODEL SYSTEMS DEVELOPMENT AND BIOLOGY

Lorenzo Ferri, MD, PhD, *Memorial Sloan Kettering Cancer Center*

Karol Nowicki-Osuch, PhD, *Columbia University*

Ken Lau, PhD, *Vanderbilt University Medical Center*

Discussion moderated by Adam Bass, MD and Jim Goldenring, MD, PhD

3:20 PM AFTERNOON STRETCH & COFFEE

3:45 PM RAPID FIRE ABSTRACTS

Monika Laszkowska MD, MS, *Memorial Sloan Kettering Cancer Center*

Su-Hyung Lee, DVM, PhD, *Vanderbilt University Medical Center*

Pranshu Sahgal, PhD, *Dana-Farber Cancer Institute*

Pavithra Rajagopalan, PhD, *Massachusetts General Hospital*

Qurat-ul-Ain, PhD, *University of California, San Francisco*

5:00 PM GUIDED DISCUSSION

FOCUS: BIOLOGY

5:30 PM POSTER SESSION

6:00 PM NETWORKING DINNER

AGENDA - DAY 2

FRIDAY, NOVEMBER 18

8:00 AM NETWORKING BREAKFAST & REGISTRATION

8:45 AM OPENING REMARKS

Adam Bass, MD, *Novartis Institute for Biomedical Research*

9:00 AM SESSION 3: MICROENVIRONMENT AND NEW TECHNOLOGIES

Nilay Sethi, MD, PhD, *Dana-Farber Cancer Institute*

Orit Rozenblatt-Rosen, PhD, *Genentech*

Discussion moderated by Adam Bass, MD and Matthew Stachler, MD, PhD

10:30 AM MORNING STRECH & COFFEE

10:50 AM ABSTRACT PRESENTATIONS

Rodrigo Gier, BA, *University of Pennsylvania*

Dipankar Ray, PhD, *University of Michigan*

11:30 AM SESSION 4: EMERGING THERAPEUTICS/CELL THERAPIES/ NEW ANTIBODIES

Kole Roybal, PhD, *University of California, San Francisco*

Julia Carnevale, MD, *University of California, San Francisco*

Discussion moderated by Adam Bass, MD and Sam Klempner, MD

1:00 PM NETWORKING LUNCH WITH GUIDED DISCUSSION FOCUS: CLINICAL

1:50 PM CLOSING REMARKS

ABSTRACTS

Rodrigo Gier, BA

University of Pennsylvania

Lineage-resolved transcriptional profiling of Barrett's esophagus uncovers the clonal origins of oncogenesis

Dipankar Ray, PhD

University of Michigan

A novel ubiquitin ligase independent, chaperone regulating role of GRAIL in mutant p53 stabilization

RAPID-FIRE ABSTRACTS

Monika Laszkowska, MD, MS

Memorial Sloan Kettering Cancer Center

Key factors associated with the detection of hereditary diffuse gastric cancer on endoscopy in individuals with germline CDH1 mutations

Su-Hyung Lee, DVM, PhD

Vanderbilt University Medical Center

Apposition of fibroblasts with metaplastic gastric cells promotes dysplastic transition

Pranshu Sahgal, PhD

Dana-Farber Cancer Institute

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting

Pavithra Rajagopalan, PhD

Massachusetts General Hospital

IL-6 inhibition promotes mitochondrial efficiency in esophageal adenocarcinoma

Qurat-ul-Ain, PhD

University of California, San Francisco

Dissecting immune-inflammatory microenvironment in the Barrett's esophagus to esophageal adenocarcinoma transition: A nanostring GeoMx pilot study

POSTERS

Chunyang Bao, PhD

Dana-Farber Cancer Institute

Genomic signatures of chromosomal instability in the evolution of Barrett's esophagus to esophageal adenocarcinoma

Kaumudi Bhawe, PhD

Cancer Commons

Real-World Evidence (RWE) outlines a role for community-embedded Oncology Clinical Teams (ceOCTs) in supporting precision medicine implementation for esophageal and gastric cancer patients

Osamu Kikuchi, MD, PhD

Kyoto University Hospital

Developing combination therapy with SHP2 inhibition for CIN-type gastroesophageal adenocarcinoma with KRAS amplification

Aarti Kumar, BA

Columbia University Vagelos College of Physicians and Surgeons

Alterations in serum bile acids with Barrett's esophagus and associated neoplasia

Matthew Stachler, MD, PhD

University of California, San Francisco

A clinically applicable, genomic assay detects pathogenic alterations in Barrett's esophagus patients with non-dysplastic tissue

Kulsum Tai, M.SC

McGill University

Dissecting the stromal drivers of gastroesophageal adenocarcinoma chemoresistance

SPECIAL THANKS TO OUR SPONSORS



Daiichi-Sankyo



TAIHO
ONCOLOGY



zymeworks



TARGET → RARE → CANCER → KNOWLEDGE

TCF-001 TRACK is a rare cancer precision medicine clinical trial, NCT04504604.

TRACK provides participating rare cancer patients and their physicians with personalized, actionable information to potentially inform treatment, as well as recommendations for treatments from an expert panel of rare cancer clinicians and scientists. Simultaneously, TRACK generates critical genomic data to drive a better understanding of often overlooked rare cancers.

TRACK is currently open to enrollment for:

Patients with any rare cancer (defined as a solid tumor or lymphoma occurring in less than 6 per 100,000 people per year in the US). TRACK will specifically enroll 100 patients with cholangiocarcinoma.

Patients with cancer of unknown primary.

How TRACK Works:

→ Qualifying patients can enroll in TRACK from their home using a remote consenting system, allowing full participation with no requirement to travel or change their treating physician.



→ Patients enrolled in TRACK receive comprehensive genomic profiling (FoundationOne® CDx and FoundationOne® Liquid CDx) at no cost.

→ The TRACK Virtual Molecular Tumor Board, composed of field-leading rare cancer experts, convenes to review the resulting reports and other data, and provides treatment recommendations to the patient and their treating physician.



→ Over the year that follows, the TCF study team collects updated study-related medical information from each patient. In addition, comprehensive genomic profiling of blood is repeated multiple times to identify new alterations which could potentially drive additional treatment recommendations.



To learn more about TRACK and how to enroll, visit www.targetcancerfoundation.org/track, or call 617-299-0389.

Passion for Innovation.
Compassion for Patients.™



Daiichi Sankyo celebrates the work of the Target Cancer Foundation and the extraordinary strides being made in gastroesophageal cancer to bring much needed treatments and support to patients, caregivers and all those impacted.

We're proud to support the 2022 Think Tank on Advancing Gastroesophageal Cancer Research. Through continued collaborations, we can all make a meaningful difference in cancer care for the fearless people thriving with gastroesophageal cancer and their families.

To learn more about our work in oncology, visit DaiichiSankyo.us.



**SOLVE
ON.**

LEARN MORE AT
incyte.com



Collaborative

Dynamic



Patient-Centered

At Taiho Oncology, our mission is to improve the lives of patients with cancer, their families, and their caregivers.

Taiho continues to deliver innovative products to the U.S. and global marketplace. The oncology patient, and their support systems, are at the center of our every activity.

Proud Supporter of the 2022 Target Cancer Foundation
Think Tank on Advancing Gastroesophageal Cancer Research



United in sending patients home, disease free

Zymeworks is dedicated to making targeted therapies that meaningfully improve the lives of people with cancer. Our HER2-targeted antibody zanidatamab is being evaluated in pivotal clinical trials in biliary tract cancer and gastric cancer.

WWW.ZYMEWORKS.COM

TWITTER [@ZYMEWORKSINC](https://twitter.com/ZYMEWORKSINC)

TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.



For more information, visit
www.targetcancerfoundation.org